Kotak Institutional Equities said even its conservative Nifty estimates may have downside risks, as exports and commodity-oriented sectors may contribute to 35 per cent of Nifty FY25 net profits.

RIL, Adani Ports, Divis Labs, TechM, Bajaj Auto: Half of Nifty shares trade at huge premium; stock picks

Companies including Infosys, SBI, Titan, Britannia Industries, Divis Labs, Ambuja Cements, Bank of India and more may remain under the spotlight before the opening bell on Monday, August 6.

Stocks in news: Infosys, SBI, Titan, Airtel, Britannia, Divis Labs and Ambuja Cements

Shares of Divis Laboratories fell 2.41 to Rs 4870 per share on the BSE in Monday’s intraday deals. This came despite the company delivering a 21 percent year-on-year (YoY) rise in net profit

Earnings growth priced-in Divi’s Labs stock, niche biz to expand: Analysts

A total of 15,796 shares changed hands on the counter till 12:27PM (IST)

Divis Labs shares decline 2.21% as Sensex slides

Divi's Laboratories Q1: Revenue Grows, Profit Below Est; Mgmt Positive On GLP-1 Drug Opportunities

Upcoming results: Oil and Natural Gas Corporation(ONGC), Bharti Airtel, Marico, BEML, Bharti Hexacom, Avanti Feeds, BLS International, Motherson Sumi Wiring India, Brigade Enterprises, Century Plyboards, Deepak Nitrite, Devani International, Gujarat State Fertilizers and Chemicals (GSFC), H.G. Infra Engineering, Honeywell Automation, Orient Cement, Sandhur Maganese and Iron Ores, Schneider Electric Infrastructure, Syrma SGS Technology, Tata Chemicals, Triveni Turbine, V-Mart Retail, VRL Logistics.

Stock Alert: Britannia Inds, Titan Company, Divis Lab, State Bank of India, Delhivery, Sheela Foam

Key Stocks In Focus: SBI, Titan, Divi's Laboratories, Britannia, LIC Housing Finance, Delhivery, IEX

The Street will react to major earnings reports from SBI, Divis Laboratories, Titan, and Britannia when markets resume trading on Monday. Additionally, 922 BSE-listed companies will announce April-June earnings, including Bharti Airtel and Tata Power. Indian markets will take cues from US market closures and GIFT Nifty futures.

Q1 results, IPO action among 10 factors that will steer D-Street this week

The pharma major’s consolidated net profit jumped 20.79% to Rs 430 crore in Q1 FY25 as against Rs 356 crore recorded in Q1 FY24.

Divis Lab Q1 PAT climbs 21% YoY to Rs 430 cr

On the technical charts, the 200-day moving average of the stock stood at Rs 3903.31.

Shares of Divis Labs rise as Nifty drops

Discover the Divi’s Laboratories Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a top-performing stock. Keep track of Divi’s Laboratories’s latest details, including: Last traded price 4944.25, Market capitalization: 130695.49, Volume: 19961, Price-to-earnings ratio 81.68, Earnings per share 60.27. Our liveblog offers a holistic view of Divi’s Laboratories by examining both fundamental and technical indicators. Stay ahead of market trends with breakingnews that can impact Divi’s Laboratories’s performance. Our market analysis and expert opinions provide valuable insights to guide your investment decisions. Join us on the Divi’s Laboratories Stock Liveblog and stay informed in this dynamic market landscape. The data points are updated as on 01-08-2024 09:20 IST

Price Updates: Divis Laboratories Hits New 52-Week High at Rs 4953.20, Registers 0.61% Increase - The Economic Times

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Divi's Laboratories Limited is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs) and Intermediates. Its products include Generic APIs, Intermediates, Peptide Building Blocks and Carotenoids.